drugset
drugset / Trial / NCT07415980

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

NCT07415980 ↗

Phase 1/2 Not yet recruiting 68 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Timeline

Start
2026-04-01
Primary completion
2028-04-01
Completion
2031-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Polatuzumab Vedotin Other / unclassified 1.8 mg/kg Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Tucidinostat Small molecule 20 mg Oral

Indications

diffuse large B-cell lymphoma